If a drug that's known to inhibit STAT3 and cause mitochondrial uncoupling results in cytotoxicity that is unique to SU-DHL-1 cell line but not in other cancer cells, what may be the reason for this?
Hello Min Gui Jang
There are differences between cancer cell lines with respect to key mutations that play a role in many different biological processes in the cell like impaired apoptosis, increased drug efflux which could cause differing drug sensitivity.
Generally, cell lines appear to respond to drugs in two broad patterns.
One group of drugs, primarily targeting machinery involved in the cell cycle, protein chaperoning or DNA repair which elicit similar patterns of response across all cell lines.
A second group of drugs, trigger responses that are specific to cell type. Different cell types respond to these drugs in qualitatively different ways. Such drugs largely target the signaling pathways that are disrupted by oncogenic mutations.
So, wherever possible, cell lines should be selected that most closely resemble the genomic alterations of the tumor subtype being studied. No individual cell line can be representative of all cancers derived from a single tissue.
I hope this helps.
Best.
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Cell Biology
- Culture Cells
- Cell Line